iBio Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Narrative) (Details)

Stockholders' Equity (Narrative) (Details) - USD ($)															1 Months Ended			3 Months Ended	5 Months Ended	6 Months Ended	8 Months Ended	12 Months Ended
Stockholders' Equity (Narrative) (Details) - USD ($)	Oct. 29, 2020	Jun. 30, 2020	Jun. 20, 2020	Jun. 17, 2020	May 13, 2020	Mar. 19, 2020	Oct. 29, 2019	Oct. 28, 2019	Jun. 26, 2018	Nov. 27, 2017	Feb. 23, 2017	Apr. 13, 2016	Apr. 07, 2016	Jan. 13, 2016	Aug. 31, 2020	Jul. 27, 2020	Jun. 30, 2020	Oct. 13, 2020	Nov. 25, 2020	Dec. 31, 2019	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Mar. 19, 2020	Jun. 30, 2019	Feb. 20, 2020	Jun. 20, 2018
Stockholders' Equity [Line Items]
Warrant exchange and deemed dividend																								$ (3,300,000)
Deemed dividends on common stock recognized																							$ 21,560,000
Warrants to purchase shares of Common Stock																				14,999,998							9,595,002
Exercise of warrants (in shares)																				6,600,000	29,100,000
Proceeds from exercise of warrants																					$ 6,400,000			$ 6,330,000
Shares of common stock issued for the cashless exercise of Warrants																					5,900,000
Cashless exercise of warrants reducing balance owed for notes payable – warrant exchange																					$ 1,300,000
Costs related to the warrant exchange offset against additional paid-in capital																					$ 313,000
Warrants outstanding																						0	0
Common stock, par value (in dollars per share)		$ 0.001															$ 0.001				$ 0.001	$ 0.001	$ 0.001	$ 0.001
Preferred Stock, shares authorized											1,000,000											1,000,000	1,000,000
Number of common stock issued upon conversion																								5,887,997		2,470,000
Proceeds from sale of shares, gross		$ 18,400,000					$ 5,000,000
Cost related to issuance of shares																							$ 4,713,000	$ 2,170,000
Warrants, exercise price per share			$ 1.47																			$ 0.20	$ 0.20
Common Stock, Shares Authorized		275,000,000															275,000,000				275,000,000	275,000,000	275,000,000	275,000,000
Proceeds from Warrant Exercises																					$ 6,400,000			$ 6,330,000
Stock Issued During Period, Shares, Warrants Exercised																				6,600,000	29,100,000
UBS Securities, LLC ("UBS") [Member]
Stockholders' Equity [Line Items]
Number of shares issued																		10,400,000				17,400,000
Proceeds from sale of shares, gross																						$ 37,800,000
Cost related to issuance of shares																						$ 1,270,000
Commission rate				3.00%
Series A Common Stock Purchase Warrants [Member]
Stockholders' Equity [Line Items]
Number of shares issued							25,000,000													3,300,000
Warrants, exercise price per share							$ 0.22
Number of stocks sold							1
Number of stock issued on each unit of stock sold							1
Term of the warrants							2 years
Series B Common Stock Purchase Warrants [Member]
Stockholders' Equity [Line Items]
Number of shares issued							25,000,000
Warrants, exercise price per share							$ 0.22
Number of stocks sold							1
Number of stock issued on each unit of stock sold							1
Term of the warrants							7 years
Warrant [Member]
Stockholders' Equity [Line Items]
Number of stocks sold							2
Common Stock [Member]
Stockholders' Equity [Line Items]
Warrant exchange and deemed dividend																								$ 15,000
Warrant exchange and deemed dividend (in shares)																								15,000,000
Exercise of warrants (in shares)																								35,000,000
Number of shares issued							2,450,000
Warrants, exercise price per share																						$ 0.20	$ 0.20
Stock Issued During Period, Shares, Warrants Exercised																								35,000,000
Common Stock [Member] \| UBS Securities, LLC ("UBS") [Member]
Stockholders' Equity [Line Items]
Number of shares issued																							2,400,000
Proceeds from sale of shares, net of issuance cost																							$ 5,550,000
Series A Preferred Stock [Member]
Stockholders' Equity [Line Items]
Preferred stock, par value (in dollars per share)																												$ 0.001
Preferred Stock, shares authorized																												1,000,000
Number of preferred stock converted																								3,987		2,223
Preferred stock, shares outstanding (in shares)		0															0				0	0	0	0
Convertible preferred stock, conversion price	$ 0.20																											$ 0.90
Convertible preferred stock, value used to get to conversion price	$ 1,000
Series B Preferred Stock [Member]
Stockholders' Equity [Line Items]
Preferred stock, par value (in dollars per share)																												$ 0.001
Preferred Stock, shares authorized																												1,000,000
Number of new shares issued									$ 5,785
Number of common stock issued upon conversion															28,925,000
Preferred stock, shares outstanding (in shares)		5,785															5,785				5,785			5,785
Convertible preferred stock, conversion price							$ 0.20																					$ 0.90
Convertible preferred stock, value used to get to conversion price			$ 1,000
Maximum common stock percentage threshold for the right to exercise Preferred stock							48.00%
Series C Preferred Stock [Member]
Stockholders' Equity [Line Items]
Preferred stock, par value (in dollars per share)								$ 0.001
Preferred Stock, shares authorized								1,000,000
Number of new shares issued							$ 4,510
Number of common stock issued upon conversion																					22,550,000
Preferred stock, shares outstanding (in shares)		0															0				0	0	0	0
Convertible preferred stock, conversion price								$ 0.20
Convertible preferred stock, value used to get to conversion price								$ 1,000
Maximum common stock percentage threshold for the right to exercise Preferred stock								4.99%
Maximum ownership through conversion with prior notice								9.99%
Number of shares issued							4,510
Series C Preferred Shares, and Warrants [Member]
Stockholders' Equity [Line Items]
Warrants, exercise price per share																						$ 1,000	$ 1,000
iBio CMO Preferred Tracking Stock [Member]
Stockholders' Equity [Line Items]
Preferred Stock, Dividend Rate, Percentage																							2.00%
Preferred Stock, Dividends Per Share, Declared																							$ 0
Dividends Payable		$ 871,000															$ 871,000				$ 871,000	$ 1,131,000	$ 1,131,000	$ 871,000
Omnibus Incentive (the 2020) Plan [Member]
Stockholders' Equity [Line Items]
Shares available for grant under the plan																						32,000,000	32,000,000
Underwritten Public Offering [Member] \| Series A Preferred Stock [Member]
Stockholders' Equity [Line Items]
Number of new shares issued									$ 6,300
Underwritten Public Offering [Member] \| Series C Preferred Shares, and Warrants [Member]
Stockholders' Equity [Line Items]
Proceeds from sale of shares, net of issuance cost							$ 4,520,000
Common Stock Purchase Agreement [Member] \| Lincoln Park Capital Fund, LLC [Member]
Stockholders' Equity [Line Items]
Aggregate value of shares offered for sale						$ 50,000,000																			$ 50,000,000
Number of shares issued						815,827										2,670,000	16,800,000
Proceeds from sale of shares, gross																$ 6,790,000
Proceeds from sale of shares, net of issuance cost					$ 1,090,000												$ 18,400,000
Shares Issued, Price Per Share					$ 1.09
Sale of stock, agreement period						36 months
Maximum obligation under each Regular Purchase						$ 5,000,000																			$ 5,000,000
Floor price						$ 0.20																			$ 0.20
Common Stock Purchase Agreement [Member] \| Eastern Affiliate [Member]
Stockholders' Equity [Line Items]
Exercise of warrants (in shares)														178,400
Proceeds from exercise of warrants														$ 945,000
Number of shares agreed to be issued, maximum													650,000	650,000
Number of shares issued												650,000		350,000
Proceeds from sale of shares, gross														$ 2,177,000
Proceeds from sale of shares, net of issuance cost												$ 4,043,000
Shares Issued, Price Per Share														$ 6.22
Sale of stock, agreement period												3 years
Equity Method Investment, Ownership Percentage										38.00%		38.00%
Proceeds from Warrant Exercises														$ 945,000
Stock Issued During Period, Shares, Warrants Exercised														178,400
Amended Stock Purchase Agreement [Member] \| Eastern Affiliate [Member]
Stockholders' Equity [Line Items]
Sale of stock, agreement period									2 years
Equity Method Investment, Ownership Percentage Threshold to purchase shares									40.00%
At-The-Market Offering [Member] \| Common Stock [Member] \| UBS Securities, LLC ("UBS") [Member]
Stockholders' Equity [Line Items]
Number of shares issued																			10,400,000
Proceeds from sale of shares, net of issuance cost																			$ 26,700,000
Exchange Agreement [Member] \| iBio CMO Preferred Tracking Stock [Member] \| Bioprocessing (iBio CDMO) [Member]
Stockholders' Equity [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent											70.00%
Number of LLC interest units exchanged for each share of preferred tracking stock											29,990,000
Proceeds from sale of shares, net of issuance cost											$ 13,000,000
Exchange Agreement [Member] \| iBio CMO Preferred Tracking Stock [Member] \| After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] \| Bioprocessing (iBio CDMO) [Member]
Stockholders' Equity [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent											99.99%
Exchange Agreement [Member] \| Eastern Affiliate [Member] \| iBio CMO Preferred Tracking Stock [Member] \| Bioprocessing (iBio CDMO) [Member]
Stockholders' Equity [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent																						70.00%	70.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners											30.00%											30.00%	30.00%
Exchange Agreement [Member] \| Eastern Affiliate [Member] \| iBio CMO Preferred Tracking Stock [Member] \| After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] \| Bioprocessing (iBio CDMO) [Member]
Stockholders' Equity [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners											0.01%
Maximum [Member] \| UBS Securities, LLC ("UBS") [Member]
Stockholders' Equity [Line Items]
Reimbursement of fees and disbursements				$ 50,000
Maximum [Member] \| Common Stock Purchase Agreement [Member] \| Lincoln Park Capital Fund, LLC [Member]
Stockholders' Equity [Line Items]
Number of shares agreed to be issued, maximum					1,000,000	1,000,000
Maximum [Member] \| Common Stock Purchase Agreement [Member] \| Eastern Affiliate [Member]
Stockholders' Equity [Line Items]
Equity Method Investment, Ownership Percentage Threshold to purchase shares										40.00%
Maximum [Member] \| Amended Stock Purchase Agreement [Member] \| Eastern Affiliate [Member]
Stockholders' Equity [Line Items]
Equity Method Investment, Ownership Percentage Threshold to purchase shares									48.00%
Maximum [Member] \| At-The-Market Offering [Member] \| UBS Securities, LLC ("UBS") [Member]
Stockholders' Equity [Line Items]
Aggregate value of shares offered for sale				$ 72,000,000